VEGF-A antibody
Principal name
VEGF-A antibody
Alternative names for VEGF-A antibody
VEGFA, VEGF, VPF, Vascular endothelial growth factor A, Vascular permeability factor
SwissProt ID
P15691 (Bovin), P15692 (Human), P16612 (Rat), P26617 (Cavpo), P49151 (Pig), P50412 (Sheep), P67964 (Chick), Q00731 (Mouse), Q99PS1 (Mesau), Q9GKR0 (Horse), Q9MYV3 (Canfa)
Ncbi ID
NP_001020537.2, NP_001003175.2, NP_001020421.2, NP_001103803.1, 9606, NP_776641.1, NP_001020541, NP_001020428, 10090, 10116, NP_001103803, NP_001020537, NP_001020421, NM_001204385, NP_114024.2, NP_001020539.2, NP_001165097, NP_001103804, NP_033531, AAA40547, AAL07526.1, NM_001033756, NM_001025366, NM_001025368, NM_001025370, NP_001103736, NP_001028928, NP_003367, NM_001025250, NM_001110336, NM_001110333, NM_001025257, NM_001110266, NM_001110267, NM_001110268, NM_031836, NM_001110334, NM_001110335, NM_001171630, NM_001171628, NM_001171627, NM_001171625, NM_001171624, NM_001171623, NM_001171622, NM_001025369
Available reactivities
Available hosts
Available applications
Paraffin Sections (P), Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Functional assay (FN), Immunocytochemistry/Immunofluorescence (ICC/IF), Immunoprecipitation (IP), Frozen Sections (C), Radioimmunoassay (R), ELISA (detection) (E(detection))
Background of VEGF-A antibody
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and in adults . It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues in a cystine knot structure and formation of anti-parallel disulfide-linked dimers . Alternately spliced isoforms of 120, 164, and 188 amino acids (aa) have been found in rats and mice, while 121, 145, 165, 183, 189, and 206 aa isoforms have been identified in humans . In humans, VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189 . The same pattern may exist in rats and mice. Isoforms other than VEGF120 and VEGF121 contain basic heparin-binding regions and are not freely diffusible . Rat VEGF164 shares 97% aa sequence identity with corresponding regions of mouse, 88% with human and bovine, 89% with porcine and canine, and 90% with feline and equine VEGF. VEGF is expressed in multiple cells and tissues including skeletal and cardiac muscle , hepatocytes , osteoblasts , neutrophils , macrophages , keratinocytes , brown adipose tissue , CD34+ stem cells , endothelial cells , fibroblasts, and vascular smooth muscle cells . VEGF expression is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, Oncostatin M, and TNF-. . The isoforms are differentially expressed during development and in the adult .
VEGF dimers bind to two related receptor tyrosine kinases, VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) and induce their homodimerization and autophosphorylation . These receptors have seven extracellular immunoglobulin-like domains and an intracellular split tyrosine kinase domain. They are expressed on vascular endothelial cells and a range of non-endothelial cells. Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity . VEGF165 also binds the semaphorin receptor, neuropilin-1, which promotes complex formation with VEGF R2 .
VEGF is best known for its role in vasculogenesis. During embryogenesis, VEGF regulates the proliferation, migration, and survival of endothelial cells , thus regulating blood vessel density and size but playing no role in determining vascular patterns. VEGF promotes bone formation through osteoblast and chondroblast recruitment and is also a monocyte chemoattractant . In postnatal life, VEGF maintains endothelial cell integrity and is a potent mitogen for micro- and macro-vascular endothelial cells. In adults, VEGF functions mainly in wound healing and the female reproductive cycle . In diseased tissues, VEGF promotes vascular permeability. It is thus thought to contribute to tumor metastasis by promoting both extravasation and tumor angiogenesis . Various strategies have been employed therapeutically to antagonize VEGF-mediated tumor angiogenesis . Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus .
General readings
Conn, G. et al. (1990) J. Biol. Chem. 87:2628.
Ishii, H. et al. (2001) Arch. Oral Biol. 46:77.
Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
Richardson, R.S. et al. (1999) Am. J. Physiol. 277:H2247.
Sugishita, Y. et al. (2000) Biochem. Biophys. Res. Commun. 268:657.
Yamane, A. et al. (1994) Oncogene 9:2683.
Goad, D.L. et al. (1996) Endocrinology 137:2262.
Gaudry, M. et al. (1997) Blood 90:4153.
Mclaren, J. et al. (1996) J. Clin. Invest. 98:482.
Diaz, B.V. et al. (2000) J. Biol. Chem. 275:642.
Asano, A. et al. (1997) Biochem. J. 328:179.
Bautz, F. et al. (2000) Exp. Hematol. 28:700.
Namiki, A. et al. (1995) J. Biol. Chem. 270:31189.
Nauck, M. et al. (1997) Am. J. Respir. Cell. Mol. Biol. 16:398.
Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.
Neufeld, G. et al. (1999) FASEB. J. 13:9.
Kowalewski, M.P. et al. (2005) Accession #ABB82619.
Pan, Q. et al. (2007) J. Biol. Chem. 282:24049.
Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
Breier, G. (2000) Semin. Thromb. Hemost. 26:553.
Barleon, B. et al. (1996) Blood 87:3336.
Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
Thurston, G. (2002) J. Anat. 200:575.
Grothey, A. and E. Galanis (2009) Nat. Rev. Clin. Oncol. 6:507.
Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
This antibody stained formalin-fixed, paraffin-embedded sections of Human breast invasive ductal carcinoma. The recommended concentrations are 2.5-5.5 µg/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 Sodium Citrate buffer is recommended.
This antibody stained formalin-fixed, paraffin-embedded sections of Human breast invasive ductal carcinoma. The recommended concentrations are 2.5 - 5.5 µg/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 Sodium Citrate buffer is recommended.
SDS-PAGE analysis of recombinant human VEGF165. Sample was loaded in 15% SDS-polyacrylamide gel under non-reducing condition and stained with Coomassie blue.
VEGF165-induced proliferation of HUVE cells. HUVECs were stimulated with increasing amounts of human VEGF165.
Western blot analysis using DM3519P with different isoforms of recombinant human VEGF-A.
Western blot analysis of human VEGF-A isoforms 121, 165 and 189 (all produced in E. coli) under reducing (left panel) and non-reducing conditions (right panel).
VEGF-A Sandwich-ELISA using VEGF189 as standard. Mouse anti-human VEGF-A Antibody (Cat.-No DM3520P) was used as capture antibody, Biotinylated mouse anti-Human VEGF-A Antibody Clone 339/H2 was used for detection.
Immunohistochemistry with a paraffin-bedded section of human Glioblastoma tissue.
Immunofluorescence staining of VEGF-A in a mixture of primary human dermal lymphatic endothelial cells (HDLEC) and human dermal normal fibroblasts with monoclonal mouse anti-Human VEGF-A Clone: 7G7 Cat.-No DM3521P.The cells were pretreated with 0,1% Triton X100. Control with goat anti-mouse ALEXA Flour 488, 1:600).
Western analysis of recombinant human VEGF165, mouse VEGFG164 and human VEGF121 using a monoclonal mouse anti-human VEGF-A antibody Cat.-No DM3521P. There is no cross reactivity with mouse VEGF164.
VEGF-A Sandwich-ELISA using the monoclonal mouse antihuman VEGF-A antibody Cat.-No DM3521P as capture antibody and recombinant human VEGF189 as standard. The Biotinylated monoclonal mouse anti-human VEGF-A antibody Cat.-No DM3521B was used for detection.
Western analysis of recombinant Human / Mouse VEGF-A and PlGF-1 using a polyclonal antibody directed against a highly pure N-terminal peptide of native Human VEGF165 [Ala27 – Tyr47].
The antibody recognizes the unreduced Human form very weak. There is no signal for the unreduced Mouse VEGF-A. There is a clear cross reactivity with the reduced Mouse VEGF-A visible.
The antibody recognizes the unreduced Human form very weak. There is no signal for the unreduced Mouse VEGF-A. There is a clear cross reactivity with the reduced Mouse VEGF-A visible.
Immunohistochemistry on paraffin-embedded sections (Human Glioblastoma: perinecrotic area) using the antigen-affinity purified anti VEGF-A antibody DP3520S. The experiments were performed by Dr. Till Acker and Prof. K.H. Plate, Neurological Institute, Neuropathology, Deutschordenstr. 45, 60528 Frankfurt, Germany.
Immunohistochemistry on paraffin-embedded sections (Mouse E17: ventricular zone of the CNS) using the antigen-affinity purified anti-murine VEGF-A antibody DP3520S. The experiments were performed by Dr. Till Acker and Prof. K.H. Plate, Neurological Institute, Neuropathology, Deutschordenstr. 45, 60528 Frankfurt, Germany.
Immunohistochemistry on paraffin-embedded sections (Mouse E17: ventricular zone of the CNS) using the antigen-affinity purified anti-murine VEGF-A antibody DP3520P. The experiments were performed by Dr. Till Acker and Prof. K.H. Plate, Neurological Institute, Neuropathology, Deutschordenstr. 45, 60528 Frankfurt, Germany.
Immunohistochemistry on paraffin-embedded sections (Human Glioblastoma: perinecrotic area) using the antigen-affinity purified anti VEGF-A antibody DP3520P. The experiments were performed by Dr. Till Acker and Prof. K.H. Plate, Neurological Institute, Neuropathology, Deutschordenstr. 45, 60528 Frankfurt, Germany.
Western analysis of recombinant Mouse VEGF164 (Cat.-No DA3518X), Human VEGF165 (Cat.-No DA3514X), Human PlGF-1 (Cat.-No DA3508), Human FGF-2 and Human VEGF-C (Cat.-No AR01001PU-S) using a polyclonal Rabbit anti-Mouse VEGF-A antibody (Cat.-No DP3520P). There is a strong cross reactivity with human VEGF165 but not with human PlGF-1, FGF-2 and VEGF-C.
Immunohistochemistry: This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentrations are 5.0 µg/ml-15.0 µg/ml with a 30 minute incubation at room temperature or an overnight incubation at 4C. Tissue samples were provided by the Cooperative Human Tissue Network which is funded by the National Cancer Institute.
Immunohistochemistry of VEGF staining of Paraffin Sections of Bovine follicules using AP02022SU VEGF antibody. Antigen retrieval was performed by heating the dewaxed sections 4x to 95°C for 5 min. The section was then treated with Hydrogen Peroxide (1%) in methanol for 30 min to block endogenous peroxidase. The section was incubated with AP02022SU (1/300) overnight, followed by staining with ABC method. DAB in 0.0006% Hydogen Peroxide/0.05M Tris buffer (pH7.6) was used as the chromogen. This antibody stains the cytoplasm of granulosa and theca cells of mature follicules. Scale bar: 100 µm. Berisha B et al. (2002) J. Endocrinol. 167(3): 371-382.
Western Blot analysis AP02022SU VEGF antibody specificity. Differenet recombinant Human (rh) and Recombinant Bovine (rb) VEGF proteins were separated by SDS-PAGE and immunoblotted with AP02022SU (1/10,000). Lane 1: rhVEGF165 (200ng). Lane 2: rhVEGF189 (cell lysate). Lane 3: rbVEGF164 (50ng). Lane 4: rbVEGF164 (100ng). Lane 5: rbVEGF164 (100ng) with AP02022SU preadsorbed with 15 mg/ml of rhVEGF165.Lane M: Rainbow Marker.Berisha B et al. (2000) Biol. Reprod 63 (4): 1106-14.
Western Blot analysis of VEGFA expression in transfected 293T cell line (H00007422-T01) by VEGFA MaxPab polyclonal antibody.Lane 1: VEGF transfected lysate(16.17 KDa).Lane 2: Non-transfected lysate.
Wester blot analysis of 0.5 ug of recombinant human VEGFA.
Formalin-fixed and paraffin-embedded human breast carcinoma reacted with VEGFA polyclonal antibody ( Cat # PAB4878 ) , which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry ; clinical relevance has not been evaluated.
Western blot analysis of VEGFA polyclonal antibody ( Cat # PAB4878 ) ( arrow ) . 293 cell lysate ( 2 µg/lane ) either nontransfected ( Lane 1 ) or transiently transfected with the VEGF1 gene ( Lane 2 ) ( Origene Technologies ) . Molecular weight of monomeric VEGF1 is 27042 Da; higher observed molecular weight band is consistent with common form of disulfide linked homodimer.
Proximity Ligation Analysis (PLA) of protein-protein interactions between PGF and VEGFA. HeLa cells were stained with anti-PGF rabbit purified polyclonal 1:1200 and anti-VEGFA mouse monoclonal antibody 1:50. Signals were detected by Duolink® 30 Detection Kit 613(red), and nuclei were counterstained with DAPI (blue). Each red dot represents the detection of protein-protein interaction complex.
Western Blot analysis of VEGF expression in transfected 293T cell line by VEGF monoclonal antibody (M05), clone 3F7.Lane 1: VEGF transfected lysate(17.2 KDa).Lane 2: Non-transfected lysate.
Detection limit for recombinant GST tagged VEGF is approximately 0.3ng/ml as a capture antibody.
Recombinant human VEGF121, 207-327 aa: 15% SDS-PAGE (3 µg)
Human angiosarcoma stained with anti-VEGF antibody
Recombinant mouse VEGF, His-tagged: 15% SDS-PAGE (3 µg)
Formalin-fixed, paraffin-embedded human angiosarcoma stained with VEGFA monoclonal antibody, clone SPM225 ( Cat # MAB2544 ) at 1 : 50 for 10 min at RT. Staining of formalin-fixed tissue requires boiling tissue sections in 10 mM Citrate Buffer, pH 6.0 for 10 min followed by colling at RT for 20 min.
Immunohistochemical staining of VEGFA on formalin fixed, paraffin embedded human angiosarcoma with VEGFA polyclonal antibody.
Western blot analysis ofVEGFA in chimera transfected lysate with VEGFA polyclonal antibody ( Cat# PAB11986 ).
Immunohistochemical staining of VEGFA on formalin fixed, paraffin embedded human esophageal squamous cell carcinoma ( ESCC ) in cytoplasm DAB chromogenic reaction. Using VEGFA polyclonal antibody ( Cat # PAB12284 ).
Western Blot analysis of VEGFA expression from rat cardiac muscle tissue lyate with VEGFA polyclonal antibody ( Cat # PAB12284 ).
Western blot analysis of VEGFA expression in recombinant His-Tagged VEGFA protein.Lane 1 : 10 ng recombinant human-VEGFA.Lane 2 : 50 ng recombinant human-VEGFA.Lane 3 : 250 ng recombinant human-VEGFA.Lane 4 : 1 µg recombinant human-VEGFA.
Western blot analysis of rat Vegfa using recombinant rat Vegfa.
Western blot analysis of Vegfa using recombinant murine Vegfa.
NIH/3T3 cell proliferation was determined by BrdU incorporation method at 405 nm. This test was performed duplicate.N.C. : negative control [only 0.1% FBS]P.C. : positive control [10% FBS]
Recombinant human VEGF121, 207-327aa, His tagged
AM20384PU-N VEGFA antibody staining of Formalin-Fixed, Paraffin-Embedded Human Kidney followed by biotinylated anti-Mouse IgG secondary antibody, Alkaline Phosphatase-Streptavidin and Chromogen.
Immunohistochemical analysis of paraffin embedded ESCC sections, staining VEGF in cytoplams, DAB chromogenic reaction
Western blot analysis of rat cardiac muscle tissue lysis using VEGF antibody
SDS-PAGE analysis of recombinant Mouse VEGF-A isoforms produced in E. coli. Samples were loaded under non-reducing conditions in 15% SDS-polyacrylamide gel and stained with Silver stain.
SDS-PAGE analysis of recombinant mouse VEGF-A isoforms produced in E. coli Samples were loaded under non-reducing conditions in 15% SDS-polyacrylamide gel and stained with Silver stain.
Stimulation of cell proliferation in primary human umbilical vein endothelial cells (HUVEC) by recombinant moues VEGF-A isoforms. Values are the means (±SD) of triplicate determinations and expressed as percentage of control.
SDS-PAGE analysis of recombinant Mouse VEGF-A isoforms produced in E. coli. Samples were loaded under non-reducing conditions in 15% SDS-polyacrylamide gel and stained with Silver stain.
LNCap; . Sample Type :. LNCap cells . Primary Antibody Dilution :. 1:500. Secondary Antibody :. Anti-rabbit-HRP . Secondary Antibody Dilution :. 1:5000. Color/Signal Descriptions :. Brown: VEGFA Blue: DAPI . Gene Name :. VEGFA. Submitted by :. Christina Theodorpoulos, Queensland Univ. of Technology; VEGFA antibody - C-terminal region (ARP60981_P050) in LNCap cells using Immunohistochemistry
Human Fetal Brain; WB Suggested Anti-VEGFA Antibody. . Titration: 1.0 ug/ml. . Positive Control: Fetal Brain; VEGFA antibody - C-terminal region (ARP60981_P050) in Human Fetal Brain cells using Western Blot
Hum. Fetal Lung; Host: Rabbit. Target Name: NSUN6 . Sample Tissue: Human Fetal Lung . Antibody Dilution: 1.0ug/ml.; VEGFA antibody - C-terminal region (ARP60981_P050) in Hum. Fetal Lung cells using Western Blot
Hum. Fetal Heart; Host: Rabbit. Target Name: GNAS . Sample Tissue: Human Fetal Heart . Antibody Dilution: 1.0ug/ml.; VEGFA antibody - C-terminal region (ARP60981_P050) in Hum. Fetal Heart cells using Western Blot
Hum. Adult Placenta; Host: Rabbit. Target Name: SERPINA3 . Sample Tissue: Human Adult Placenta . Antibody Dilution: 1.0ug/ml.; VEGFA antibody - C-terminal region (ARP60981_P050) in Hum. Adult Placenta cells using Western Blot
VEGFA Antibody (Center) (AP54507PU-N) western blot analysis in K562 cell line lysates (35 µg/lane). This demonstrates the VEGFA antibody detected the VEGFA protein (arrow).
SDS-PAGE analysis of recombinant Rat VEGF164: Sample was loaded in 15% SDS-polyacrylamide gel under non-reducing conditions and stained with Silver stain.
SDS-PAGE analysis of recombinant Rat VEGF120: Sample was loaded in 15% SDS-polyacrylamide gel under non-reducing conditions and stained with Silver stain.
Proliferation of HUVECs examined by means of increased cell number in the presence of h-VEGF165 for 96h
Analysis of h-VEGF165 by SDS-PAGE (Track 1) and Protein standard (track M)
SDS-PAGE analysis of recombinant human VEGF206 produced in E. coli, Cat.-No. AR60009PU-N. Sample was loaded under reducing conditions in 15% SDS-polyacrylamide gel and stained with Coomassie blue.
VEGF206-induced proliferation of HUVE cells. HUVECs were stimulated with increasing amounts of human VEGF206 Cat.-No. AR60009PU-N.
SDS-PAGE analysis of recombinant human VEGF-A isoforms produced in E. coli. Samples were loaded under non-reducing conditions in 15% SDS-polyacrylamide gel and stained with Silver stain.
VEGF145-induced proliferation of primary human dermal lymphatic endothelial cells (HDLEC). HDLECs were stimulated with increasing amounts of human VEGF145.
Western blot analysis of human VEGF-A isoforms 121, 165 and 189 (all produced in E. coli) under reducing (left panel) and non-reducing conditions (right panel).
Western analysis of recombinant Human and Mouse VEGF-A and PlGF-1 using a monoclonal antibody directed against Human VEGF189 produced in E. coli. The antibody recognizes the unreduced and reduced protein. There is a weak cross reactivity with Mouse VEGF-A visible.
VEGF-A Sandwich-ELISA using VEGF189 as standard. Mouse anti-Human VEGF-A Antibody Cat.-No DM3520P (Clone 3C5) was used as capture antibody, Biotinylated Mouse anti-Human VEGF-A Antibody Cat.-No AM33406BT-N (Clone: 339/H2) was used for detection.
VEGF-A Sandwich-ELISA using VEGF189 as standard. Mouse anti-Human VEGF-A Antibody Cat.-No DM3520P (Clone 3C5) was used as capture antibody, Biotinylated Mouse anti-Human VEGF-A Antibody Cat.-No AM33406BT-N (Clone: 339/H2) was used for detection.
SDS-PAGE analysis of recombinant human VEGF-A isoforms produced in E. coli. Samples were loaded under non-reducing conditions in 15% SDS-polyacrylamide gel and stained with Silver stain.
VEGF189-induced proliferation of primary human dermal lymphatic endothelial cells (HDLEC). HDLECs were stimulated with increasing amounts of recombinant human VEGF189.
VEGF-A Sandwich-ELISA using the Biotinylated polyclonal anti-Mouse VEGF-A antibody (Cat.-No DP3520B) for detection and recombinant Human VEGF165 (Cat.-No DA3514X) and Mouse VEGF164 (Cat.-No DA3518X) as standard. A unbiotinylated Rabbit anti-Mouse VEGF-A antibody was used as capture antibody.
Human VEGF A (Vascular Endothelial Growth Factor A) isoform l, partial (165 aa), recombinant protein
Human VEGF A (Vascular Endothelial Growth Factor A) isoform l, partial (165 aa), recombinant protein
Representative Standard Curve
Representative Standard Curve
Representative Standard Curve
Representative Standard Curve
Representative Standard Curve
Representative Standard Curve
Immunohistochemical staining of paraffin-embedded Human Ovary tissue within the normal limits using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500042)
Immunohistochemical staining of paraffin-embedded Carcinoma of Human liver tissue using anti-VEGF mouse monoclonal antibody. (TA500042)
Immunohistochemical staining of paraffin-embedded Carcinoma of Human pancreas tissue using anti-VEGF mouse monoclonal antibody. (TA500042)
Immunohistochemical staining of paraffin-embedded Human pancreas tissue within the normal limits using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500042)
Immunohistochemical staining of paraffin-embedded Human breast tissue within the normal limits using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500042)
Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-VEGF monoclonal antibody.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VEGF (RC223789, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-VEGF.
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of breast tissue using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500288, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded colon tissue within the normal limits using anti-VEGFmouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500288, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded breast tissue within the normal limits using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500288, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Carcinoma of thyroid tissue using anti-VEGFmouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500288, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of ovary tissue using anti-VEGFmouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500288, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded endometrium tissue within the normal limits using anti-VEGFmouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500288, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded prostate tissue within the normal limits using anti-VEGFmouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500288, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded pancreas tissue within the normal limits using anti-VEGFmouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500288, Dilution 1:50)
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VEGF (RC223789, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-VEGF.
Immunohistochemical staining of paraffin-embedded Human pancreas tissue within the normal limits using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500289)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of Human breast tissue using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500289)
Immunohistochemical staining of paraffin-embedded Human breast tissue within the normal limits using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500289)
Immunohistochemical staining of paraffin-embedded Human liver tissue within the normal limits using anti-VEGF mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500289)
Anti-VEGF mouse monoclonal antibody (TA500289) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY VEGF(RC223789).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VEGF (RC223789, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-VEGF.
Western blot analysis of extracts (10ug) from 3 different cell lines by using anti-VEGF monoclonal antibody.(1:200)
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VEGFA (RC223789, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-VEGFA.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VEGFA (RC223789, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-VEGFA.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VEGFA (RC223789, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-VEGFA.
Detection of VEGFA doublet in CSF-IR/VEGFA chimera transfected lysate. ECL 10 second exposure.
Western blot analysis of VEGF1 Antibody (N-term) polyclonal antibody(Cat.#TA302292)(arrow). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the VEGF1 gene (Lane 2) (Origene Technologies). Molecular weight of monomeric VEGF1 is 27042 Da; higher observed molecular weight band is consistent with common form of disulfide linked homodimer.
(0.1ug/ml) staining of HEK293 lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
Predicted band size: 27 kDa . Positive control: Human cervical cancer tissue lysate. Recommended dilution: 1/500-2000. (Gel: 10%SDS-PAGE Lysate: 40 ug Primary antibody: 1/500 dilution Secondary antibody: Donkey anti Rabbit IgG - H&L (HRP) at 1/3000 dilution Exposure time: 10seconds)
Predicted cell location: Cytoplasm. Positive control: Human ovarian cancer tissue. Recommended dilution: 1/25-100 The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using VEGFA antibody at dilution 1/13, on the right is treated with the synthetic peptide. (Original magnification:x200)
Predicted band size: 35 kDa . Positive control: 293T and 231 cell lysate. Recommended dilution: 1/500-2000. (Gel: 12%SDS-PAGE Lane1: 293T cell lysate Lane2: 231 cell lysate Lysates: 40 ug per lane Primary antibody: 1/400 dilution Secondary antibody: Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution Exposure time: 45 seconds)
Predicted cell location: Cytoplasm. Positive control: Human cervical cancer tissue . Recommended dilution: 1/25-100 The image on the left is immunohistochemistry of paraffin-embedded human cervical cancer tissue using VEGFA antibody at dilution 1/25, on the right is treated with the synthetic peptide. (Original magnification:x200)
Predicted band size: 35 kDa . Positive control: Hela, Jurkat, 293T and 231 cell lysate. Recommended dilution: 1/500-2000. (Gel: 12%SDS-PAGE Lane1: Hela, cell lysate Lane2: Jurkatcell lysate Lane3: 293T cell lysate Lane4: 231 cell lysate Lysates: 40 ug per lane Primary antibody: 1/450 dilution Secondary antibody: Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution Exposure time: 2 minutes)
Predicted cell location: Cytoplasm. Positive control: Human liver cancer tissue . Recommended dilution: 1/25-100 The image on the left is immunohistochemistry of paraffin-embedded human liver cancer tissue using VEGFA antibody at dilution 1/25, on the right is treated with the synthetic peptide. (Original magnification:x200)
IHC of human breast invasive ductal carcinoma. The recommended concentrations are 5.0 ug/ml-15.0 ug/ml with a 30-minute incubation at room temperature or an overnight incubation at 4C. An HRP-labeled polymer detection system was used with a DAB chromogen. This antibody was also tested in an HRP-biotin labeling detection system. Heat induced antigen retrieval with a pH 6.0 Sodium Citrate buffer is recommended. Optimal concentrations and conditions may vary.
This antibody stained formalin-fixed, paraffin-embedded sections of Human breast invasive ductal carcinoma. The recommended concentrations are 2.5 - 5.5 mg/ml with an overnight incubation at 4C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 Sodium Citrate buffer is recommended. Optimal concentrations and conditions may vary.
To detect mVEGF by direct ELISA (using 100 ul/well antibody solution) a concentration of 0.25-1.0 ug/ml of this antibody is required. This biotinylated polyclonal antibody, in conjunction with compatible secondary reagents, allows the detection of at least 0.2-0.4 ng/well of recombinant mVEGF.
To detect mVEGF by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.25-1.0 ug/ml of this antibody is required. This biotinylated polyclonal antibody, in conjunction with Polyclonal Anti-Murine VEGF (TA328561) as a capture antibody, allows the detection of at least 0.2-0.4 ng/well of recombinant mVEGF.
To detect mVEGF by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Biotinylated Anti-Murine VEGF (TA328560) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant mVEGF.
To detect mVEGF by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Biotinylated Anti-Murine VEGF (TA328560) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant mVEGF.
To detect mVEGF by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Biotinylated Anti-Murine VEGF (TA328560) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant mVEGF.
To detect Rat VEGF by direct ELISA (using 100 ul/well antibody solution) a concentration of 0.25-1.0 ug/ml of this antibody is required. This biotinylated polyclonal antibody, in conjunction with compatible secondary reagents, allows the detection of at least 0.2-0.4 ng/well of recombinant Rat VEGF.
To detect Rat VEGF by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.25-1.0 ug/ml of this antibody is required. This biotinylated polyclonal antibody, in conjunction with Polyclonal Anti-Rat VEGF (TA328599) as a capture antibody, allows the detection of at least 0.2-0.4 ng/well of recombinant Rat VEGF.
To detect Rat VEGF by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Biotinylated Anti-Rat VEGF (TA328598) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Rat VEGF.
To detect Rat VEGF by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Biotinylated Anti-Rat VEGF (TA328598) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Rat VEGF.
Western blot analysis of extracts of various cell lines, using VEGFA antibody.
Western Blot: VEGF Antibody (VG76e) [TA336482] - Analysis of VEGF in human kidney protein (30ug).
Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [TA336482] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.
Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [TA336482] - Vegf in sheep tonsil. Image from verified customer review.
Western Blot: VEGF Antibody (VG1) [TA336487] - HUVEC and 293T Cells tested at 1:1000. Image provided by verified customer review.
Western Blot: VEGF Antibody (VG1) [TA336487] - Western blot analysis of VEGF in human kidney protein using TA336487.
Immunohistochemistry-Paraffin: VEGF Antibody (VG1) [TA336487] - Analysis of Vascular Endothelial GF formalin-fixed paraffin embedded human angiosarcoma.
Western blot analysis of VEGF expression in A431 cells
Human recombinant VEGF 165 produced in yeast was resolved by electrophoresis, transferred to nitrocellulose and probed with rabbit anti-VEGF polyclonal antibody. Proteins were visualized using a donkey anti-rabbit secondary conjugated to HRP and a chemiluminescence detection system. This antibody detects reduced VEGF consistent with the molecular weight shown (approximately 22-24 kD) as well as unreduced VEGF (data not shown).
The VEGF-165 antibody (L308D10) was tested with both immunoprecipitation and Western blot analysis. The supernatant of cells over-expressing VEGF-165 was tested. Lane 1 was immunoprecipitated with mouse IgG control antibody and lane 2 was immunoprecipitated with VEGF-165 antibody (L308D10). Western blot analysis was performed using rabbit anti-human VEGF antibody (poly6275).
Human Angiosarcoma stained with anti-Vascular Endothelial Growth Factor (VEGF) antibody.
Human Angiosarcoma stained with anti-Vascular Endothelial Growth Factor (VEGF) antibody.
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| AP01112PU-N | VEGF-A antibody |
||||||
 |
Goat | Purified | Hu | E, FN, WB |
0.1 mg /
€340.00
|
||
| OriGene Technologies GmbH | |||||||
| AP01112PU-S | VEGF-A antibody |
||||||
|
Goat | Purified | Hu | E, FN, WB |
50 µg /
€250.00
|
||
| OriGene Technologies GmbH | |||||||
| DM3519P | VEGF-A (Isoform 165) antibody |
||||||
 |
Mouse | IgG1 | 3 | Purified | Hu | E, FN, WB |
0.2 mg /
€330.00
|
| OriGene Technologies GmbH | |||||||
| DP3504 | VEGF-A (Isoform 165) antibody |
||||||
 |
Rabbit | Azide Free | Hu | E, FN, IP |
0.2 mg /
€290.00
|
||
| OriGene Technologies GmbH | |||||||
| DP3504S | VEGF-A (Isoform 165) antibody |
||||||
|
Rabbit | Azide Free | Hu | E, FN, IP, WB |
0.1 mg /
€230.00
|
||
| OriGene Technologies GmbH | |||||||
| PP1073P1 | VEGF-A antibody |
||||||
 |
Rabbit | Aff - Purified | Hu | E, FN, WB |
50 µg /
€250.00
|
||
| OriGene Technologies GmbH | |||||||
 +2 additional images |
|||||||
| PP1073P2 | VEGF-A antibody |
||||||
|
Rabbit | Aff - Purified | Hu | E, FN, WB |
0.1 mg /
€340.00
|
||
| OriGene Technologies GmbH | |||||||
| +2 additional images |
|||||||
| PP1113P1 | VEGF-A antibody |
||||||
 |
Rabbit | Aff - Purified | Ms | E, FN, P, WB |
50 µg /
€250.00
|
||
| OriGene Technologies GmbH | |||||||
| PP1113P2 | VEGF-A antibody |
||||||
|
Rabbit | Aff - Purified | Ms | E, FN, P, WB |
0.1 mg /
€340.00
|
||
| OriGene Technologies GmbH | |||||||
